Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations.

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

Alliance A091802 is a randomized phase II trial of avelumab (800 mg IV once every 2 weeks) plus cetuximab (500 mg/m 2 IV once every 2 weeks) versus avelumab alone once every 2 weeks for up to 2 years.

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free ...

HealthDay News — For patients with BRAF V600E-mutated metastatic colorectal cancer, progression-free and overall survival are significantly longer with encorafenib plus cetuximab (EC) plus ...

HealthDay News — For patients with BRAF V600E-mutated metastatic colorectal cancer, progression-free and overall survival are significantly longer with encorafenib plus cetuximab (EC) plus ...

Sixty patients were randomized one-to-one and stratified by PD-L1 and HIV status. The primary endpoint was progression-free survival. Patients on the cetuximab plus avelumab arm had a median PFS of 11 ...

These activities are further supported by the in-vivo data demonstrating that both the NKG2A and CD3 arms contribute to the ...

Cetuximab is a chimeric monoclonal antibody of the immunoglobulin class that is directed against the human EGF receptor (EGFR). EGFR is almost invariably overexpressed in squamous cell carcinoma ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab ...